| scholarly article | Q13442814 |
| P2093 | author name string | Freeman R | |
| Snydman DR | |||
| Griffith J | |||
| Falagas ME | |||
| Werner BG | |||
| Ruthazer R | |||
| Rohrer R | |||
| P433 | issue | 5 Pt 1 | |
| P921 | main subject | orthotopic liver transplantation | Q106649759 |
| liver transplantation | Q1368191 | ||
| P304 | page(s) | 432-437 | |
| P577 | publication date | 1997-10-01 | |
| P1433 | published in | Clinical Transplantation | Q15754920 |
| P1476 | title | Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group | |
| P478 | volume | 11 |
| Q35946943 | Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins |
| Q34626941 | Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients. |
| Q35107691 | Cytomegalovirus infection in solid organ transplantation: economic implications |
| Q33807009 | Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression |
| Q36757818 | Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies |
| Q37050965 | Immunobiology of human cytomegalovirus: from bench to bedside. |
| Q35715908 | Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation |
| Q84157042 | Introduction: disease overview and risk factors |
| Q58801058 | Maternal Immunity and the Natural History of Congenital Human Cytomegalovirus Infection |
| Q33812425 | New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients |
| Q24550699 | Passive immunity in prevention and treatment of infectious diseases |
| Q45967035 | Pharmacokinetics and exposure-response analysis of RG7667, a combination of two anti-cytomegalovirus monoclonal antibodies, in a Phase 2a randomized trial to prevent cytomegalovirus infection in high-risk kidney transplant recipients. |
| Q24200991 | Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients |
| Q33999369 | Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases |
Search more.